Abstract
Forty-nine subjects received two doses of oral cholera vaccine consisting of whole cells plus recombinant B subunit; this was followed by a booster dose one year later. After the primary series, a significant (greater than twofold) increase in the levels of vibriocidal, anti-cholera toxin immunoglobulin G and anti-cholera toxin immunoglobulin A antibodies occurred in 54, 88, and 81% of the subjects, respectively. Within one year, titers decreased to levels close to baseline. A booster dose then induced rises to those which occurred after the initial vaccination. The results suggest that 1-year booster doses may be necessary to maintain immunity against cholera in Latin America.
Full Text
The Full Text of this article is available as a PDF (150.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Clemens J. D., Harris J. R., Sack D. A., Chakraborty J., Ahmed F., Stanton B. F., Khan M. U., Kay B. A., Huda N., Khan M. R. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J Infect Dis. 1988 Jul;158(1):60–69. doi: 10.1093/infdis/158.1.60. [DOI] [PubMed] [Google Scholar]
- Clemens J. D., Sack D. A., Harris J. R., Chakraborty J., Khan M. R., Stanton B. F., Kay B. A., Khan M. U., Yunus M., Atkinson W. Field trial of oral cholera vaccines in Bangladesh. Lancet. 1986 Jul 19;2(8499):124–127. doi: 10.1016/s0140-6736(86)91944-6. [DOI] [PubMed] [Google Scholar]
- Clemens J. D., Sack D. A., Harris J. R., Van Loon F., Chakraborty J., Ahmed F., Rao M. R., Khan M. R., Yunus M., Huda N. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet. 1990 Feb 3;335(8684):270–273. doi: 10.1016/0140-6736(90)90080-o. [DOI] [PubMed] [Google Scholar]
- Clemens J. D., Stanton B. F., Chakraborty J., Sack D. A., Khan M. R., Huda S., Ahmed F., Harris J. R., Yunus M., Khan M. U. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J Infect Dis. 1987 Jan;155(1):79–85. doi: 10.1093/infdis/155.1.79. [DOI] [PubMed] [Google Scholar]
- Cryz S. J., Jr, Levine M. M., Losonsky G., Kaper J. B., Althaus B. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults. Infect Immun. 1992 Sep;60(9):3916–3917. doi: 10.1128/iai.60.9.3916-3917.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Glass R. I., Svennerholm A. M., Khan M. R., Huda S., Huq M. I., Holmgren J. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis. 1985 Feb;151(2):236–242. doi: 10.1093/infdis/151.2.236. [DOI] [PubMed] [Google Scholar]
- Kaper J. B. Vibrio cholerae vaccines. Rev Infect Dis. 1989 May-Jun;11 (Suppl 3):S568–S573. doi: 10.1093/clinids/11.supplement_3.s568. [DOI] [PubMed] [Google Scholar]
- MCINTYRE O. R., FEELEY J. C. PASSIVE SERUM PROTECTION OF THE INFANT RABBIT AGAINST EXPERIMENTAL CHOLERA. J Infect Dis. 1964 Dec;114:468–475. doi: 10.1093/infdis/114.5.468. [DOI] [PubMed] [Google Scholar]
- Sanchez J., Holmgren J. Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development. Proc Natl Acad Sci U S A. 1989 Jan;86(2):481–485. doi: 10.1073/pnas.86.2.481. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Svennerholm A. M., Holmgren J., Black R., Levine M., Merson M. Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli. J Infect Dis. 1983 Mar;147(3):514–522. doi: 10.1093/infdis/147.3.514. [DOI] [PubMed] [Google Scholar]